Project Details
Description
The proposed project is a 5-year multicenter open-label trial designed to evaluate the efficacy of 40 kDa Pegylated interferon alfa-2a (Peginterferon alfa-2a) in combination with Ribavirin in the treatment of genotype-1 chronic hepatitis C (HCV, genotype-1) in African American men and women as compared to non-Hispanic whites. The Primary Aim of this proposal is to establish rates of sustained virologic response to a 48-week course of Peginterferon alfa-2a in combination with ribavirin in African Americans as compared to non-Hispanic whites with chronic HCV genotype 1 as assessed at the end of 48-week post-treatment follow-up by HCV RNA (
Status | Finished |
---|---|
Effective start/end date | 8/21/01 → 6/30/06 |
Funding
- National Institutes of Health: $156,262.00
- National Institutes of Health: $365,000.00
- National Institutes of Health: $375,000.00
- National Institutes of Health: $219,938.00
- National Institutes of Health: $175,000.00
- National Institutes of Health: $116,204.00
ASJC
- Medicine(all)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.